Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational • Not FDA-approved

Selective amylin receptor agonist research

Eloralintide

Eloralintide is an investigational selective amylin-receptor agonist studied in a controlled obesity trial. Outcomes for a manufacturer’s trial formulation do not establish the properties of a research vial.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeSelective amylin receptor agonist peptide
Evidence baseSponsor-funded randomized phase 2 trial
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch and calculation

Compound calculator

Eloralintide reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundEloralintide
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your Eloralintide calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is Eloralintide?

Eloralintide is a peptide drug candidate designed to stimulate amylin receptor pathways involved in appetite regulation. It is distinct from cagrilintide and from GLP-1 receptor agonists; studying related metabolic endpoints does not make these substances interchangeable.

What has research examined?

A randomized, placebo-controlled phase 2 study enrolled 263 participants without type 2 diabetes across several studied eloralintide groups and a placebo group. Over 48 weeks, the authors reported larger mean body-weight reductions in trial-product groups than placebo. The trial was funded by its developer. Nausea and fatigue were frequently reported, with rates varying considerably among study groups. These data concern the exact clinical-trial intervention and do not validate independently sourced material.

Important limitation

A phase 2 result does not establish regulatory approval, broad long-term safety, or equivalence of a supplier’s research vial. The different adverse-event rates are important, and this page does not recommend any amount, treatment, preparation, or administration.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.